Cardiovascular disease--the silent killer in rheumatoid arthritis

Area of Science:

• Rheumatology
• Cardiology
• Immunology

Background:

• Rheumatoid arthritis (RA) is a systemic autoimmune disease associated with significant morbidity and mortality.
• Cardiovascular disease (CVD) is a leading cause of death in RA patients, with risks exceeding those attributable to traditional risk factors alone.

Purpose of the Study:

• To examine the impact of cardiovascular disease (CVD) in rheumatoid arthritis (RA).
• To evaluate the contribution of traditional and novel risk factors to CVD in RA.
• To highlight the importance of managing cardiovascular risk in RA to reduce premature mortality.

Main Methods:

• Literature review and synthesis of existing research on RA and CVD.
• Analysis of traditional cardiovascular risk factors in the context of RA.
• Investigation of novel biomarkers and risk factors implicated in RA-associated CVD, including homocysteine, oxidised low-density lipoprotein, high-sensitivity C-reactive protein, and leptin.

Main Results:

• RA patients exhibit elevated CVD rates, independent of conventional risk factors.
• Novel risk factors such as elevated homocysteine, oxidised LDL, hs-CRP, and leptin play a significant role in RA-related CVD.
• The interplay between chronic inflammation in RA and atherogenesis contributes to accelerated cardiovascular damage.

Conclusions:

• Addressing both traditional and novel cardiovascular risk factors is crucial for managing RA patients.
• Aggressive cardiovascular risk management strategies are essential to mitigate premature mortality from coronary artery and stroke disease in RA.
• Further research is warranted to elucidate the precise mechanisms linking RA and CVD and to develop targeted therapies.